University of Texas System

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Consiglio Nazionale Delle Ricerche

University of North Texas

University of Md Anderson Cancer Center

Molecular Health Gmbh

Anil K Sood

Gabriel Lopez-Berestein

Pablo E Vivas-Mejia

Jeyshka M Reyes Gonzalez

Zhiqiang An

Ningyan Zhang

Hartmut Voss

David B Jackson

Stephan Brock

Martin Stein

Christopher G Danes

David L Volk

Chun Li

Kapil Mehta

William G Bornmann

Laszlo Prokai

Vittorio De Franciscis

Menashe Bar-Eli

Andras G Lacko

Jansina Fok

Michael J Birrer

Ariel Fernandez

Charles N Landen

Arturo Chavez-Reyes

Cristian Rodriguez-aguayo

Lokesh Ganesh L Rao

Chiyi Xiong

Lingegowda S Mangala

Yunfei Wen

Walter J McConathy

Maya P Nair

Angela Sanguino

Zheng-Hong Peng

Paola Amero

Rahul Mitra

Tomas A Bonome

Chunhua Lu

Amit Verma

Burcu Aslan

Sushovan Guha

William M Merritt

Provided herein are therapeutic peptides. In some aspects, therapeutic peptides are provided that can alter EphB4/EFNB2 signaling and can be used to treat a cancer. In some embodiments, the peptides are comprised in nanoparticles, such as core-cross-linked polymeric micelles (CCPM).

Therapeutic peptides

Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

EGFL6 specific monoclonal antibodies and methods of their use

Provided herein are DNA aptamers targeting AXL receptor kinase. The DNA aptamers may comprise a thiophosphate backbone and be chemically modified. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

DNA aptamers and use thereof for the treatment of cancer

The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.

Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer

Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the chitosan nanoparticles are coated with polylactic acid. Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease are also disclosed. For example, the treatment of ovarian cancer in a subject by inhibiting the expression of ZNF034 is disclosed.

Dual assembly nanoparticles

The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides methods for the delivery of a siNA (e.g., a siRNA) to a cell via a neutral (non-charged) liposome. These methods may be used to treat a disease, such as cancer.

Delivery of siRNA by neutral lipid compositions

Disclosed are high density lipoprotein-nucleic acid particles, wherein the particles include (a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component. Also disclosed are pharmaceutical compositions that include a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region. Methods that concern the particles and pharmaceutical compositions of the present invention are also set forth, as well as kits.

HDL particles for delivery of nucleic acids

This application describes a novel technology in drug discovery and drug-based imaging/detection: the wrapping technology. This technology is based on identified singularities in the structure of soluble proteins. In contrast with drug-design approaches based on standard structural considerations, the packing of a protein, or more precisely, its dehydron pattern, may be used as a selectivity filter to design small-molecule inhibitors. The wrapping technology described herein is a novel form of rational drug design for avoiding side effects in drug therapy and sharpening the inhibitory impact of drugs on the oncokinome.

Methods and compositions related to wrapping of dehydrons

A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject.

Pro-angiogenic genes in ovarian tumor endothelial cell isolates

A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).

Methods for treating cancer targeting transglutaminase

The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides compositions that include an siRNA targeted to an interleukin and a neutral lipid, and methods of treating a human subject with cancer involving administering to the subject a pharmaceutically effective amount of an interleukin-8 antagonist or a composition as set forth herein.

Therapeutic targeting of interleukins using siRNA in neutral liposomes

Growing community of inventors

Pearland, TX, United States of America

Anil K Sood